Corpus Intelligence IC Memo — WESTFIELD MEMORIAL HOSPITAL 2026-04-26 15:54 UTC
IC Memo — WESTFIELD MEMORIAL HOSPITAL
Investment Committee Memorandum | NY | 4 beds | Grade C | EBITDA uplift $591K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

WESTFIELD MEMORIAL HOSPITAL

CCN 330166 | CHAUTAUQUA, NY | 4 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

WESTFIELD MEMORIAL HOSPITAL is a 4-bed under-performing / distressed in CHAUTAUQUA, NY with $7.9M in net patient revenue and a -59.1% operating margin. The hospital serves a payer mix of 45.2% Medicare, 2.1% Medicaid, and 52.8% commercial.

Thesis: Turnaround. Our ML models identify $591K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -59.1% to -51.7% (+747bps).

Net Revenue HCRIS$7.9M
Current EBITDA COMPUTED$-4.7M
Operating Margin COMPUTED-59.1%
Occupancy HCRIS46.0%
Revenue / Bed COMPUTED$2.0M
Net-to-Gross HCRIS19.3%
Distress Probability ML46.7%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
0
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -59.1% places it below the state median. Among 0 size-comparable peers (2-8 beds), the median margin is 0.0%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (2-8), prioritizing same-state peers. 0 hospitals in the comp set.

HospitalStateBedsRevenueMargin
WESTFIELD MEMORIAL HOSPITAL (Target)NY4$7.9M-59.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $591K (747bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$166K+210bp18mo
Denial Rate Reduction12.0%6.5%$160K+203bp12mo
Cost to Collect4.5%2.5%$158K+200bp12mo
A/R Days Reduction5200.0%3800.0%$96K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+12bp6mo

5. EBITDA Bridge

Net Collection Rate
$166K
Denial Rate Reduction
$160K
Cost to Collect
$158K
A/R Days Reduction
$96K
Clean Claim Rate
$10K
Total EBITDA Uplift$591K
Current EBITDA$-4.7M
+ RCM Uplift+$591K
Pro Forma EBITDA$-4.1M
Current Margin-59.1%
Pro Forma Margin-51.7%
WC Released (1x)$303K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-7.2M$-24.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-7.2M$-29.8M0.00x-100.0%
Bull Case9.0x11.0x$-6.5M$-30.2M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-6.5M$-34.8M0.00x-100.0%
Bear Case11.0x10.0x$-7.9M$-25.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-7.9M$-30.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 0 hospitals with 2-8 beds
  • Same-state prioritization (n=2)
  • Comp margins: P25=nan% / P50=0.0% / P75=nan%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.